Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia.

Kidney Dis (Basel)

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Medical School, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China.

Published: December 2023

Background: Anemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis-stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain inhibitors (HIF-PHIs) have been developed to treat renal anemia through a novel mechanism. HIF-PHIs increase erythropoietin at physiologic blood concentrations and also improve the supply of hematopoietic iron. Iron is the main component of hemoglobin, and ensuring efficient iron metabolism is essential in the treatment of anemia.

Summary: HIF-PHIs may have advantages in improving iron utilization and mobilization compared to ESAs. Most HIF-PHI trials revealed a significant decline of hepcidin, increase in transferrin level and total iron binding capacity in patients. From a clinical point of view, improvements in iron metabolism should translate into reductions in iron supplementation. There are differences in the iron treatment regimentation currently used, so it is important to evaluate and timely iron supplementation across studies.

Key Messages: This review summarizes the mechanism of HIF-PHIs on improved iron metabolism and the route of iron usage in the trials for dialysis-dependent CKD and non-dialysis CKD. And this review also makes an interpretation of the clinical practice guidelines in China and recommendation by Asia Pacific Society of Nephrology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719729PMC
http://dx.doi.org/10.1159/000533304DOI Listing

Publication Analysis

Top Keywords

iron
13
iron metabolism
12
hypoxia-inducible factor
8
prolyl hydroxylase
8
hydroxylase domain
8
domain inhibitors
8
chronic kidney
8
kidney disease
8
mechanism hif-phis
8
iron supplementation
8

Similar Publications

Self-powered photoelectrochemical sensor based on molecularly imprinted polymer-coupled CBFO photocathode and AgS/SnS photoanode for ultrasensitive dimethoate sensing.

Anal Chim Acta

February 2025

CAS Key Laboratory of Separation Sciences for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, PR China. Electronic address:

Dimethoate (DIM) is one of the most extensively applied organophosphorus pesticides (OPs), which is used to boost farm productivity due to its high insecticidal efficacy. However, the excessive use of DIM can result in the extensive contamination of soil, groundwater and food. Monitoring of DIM in environmental and food samples is crucial in view of its potential health risks and environmental hazards from excessive residues.

View Article and Find Full Text PDF

Efficient Degradation of Ciprofloxacin in Water Using nZVI/g-CN Enhanced Dielectric Barrier Discharge Plasma Process.

Environ Res

January 2025

Key Laboratory of the Three Gorges Reservoir Region's Eco-Environment, Ministry of Education, Chongqing University, Chongqing 400045, China. Electronic address:

Residual antibiotics in aquatic environments pose health and ecological risks due to their persistence and resistance to biodegradation. Thus, it is crucial to develop efficient technologies for the degradation of such antibiotics. This study presents a novel approach using a nano zero-valent iron/graphitic carbon nitride (nZVI/g-CN)-enhanced dielectric barrier discharge (DBD) plasma process for the degradation of ciprofloxacin (CIP).

View Article and Find Full Text PDF

Iron Deficiency Anaemia in a Stable Chronic Intestinal Failure Cohort: Prevalence, Associations and Outcomes.

Clin Nutr ESPEN

January 2025

Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK; School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.

Background & Aims: Current estimates of the prevalence of iron deficiency anaemia (IDA) in patients with chronic intestinal failure (CIF) exceed those seen in general population, however, the studies to-date are limited with relatively small numbers of patients. The aim of the study was to determine the point prevalence of IDA in a large cohort of stable HPN-dependent adults managed by a specialist Intestinal Failure Unit.

Methods: This was a retrospective cohort study of HPN-dependent adults managed by a national UK IF Reference Centre between 01/01/2019 and 31/12/2019.

View Article and Find Full Text PDF

Berberine ameliorates seizure activity and cardiac dysfunction in pentylenetetrazol-kindling seizures in rats: Modulation of sigma1 receptor, Akt/eNOS signaling, and ferroptosis.

Neuropharmacology

January 2025

Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt; Pharmacology and Toxicology Department, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai 46612, Egypt.

Seizures can lead to cardiac dysfunction. Multiple pathways contribute to this phenomenon, of which the chaperone sigma-1 receptor (S1R) signaling represents a promising nexus between the abnormalities seen in both epilepsy and ensuing cardiac complications. The study explored the potential of Berberine (BER), a promising S1R agonist, in treating epilepsy and associated cardiac abnormalities in a pentylenetetrazol (PTZ) kindling rat model of epilepsy.

View Article and Find Full Text PDF

[Small intestine bacterial overgrowth: Myths and realities].

Aten Primaria

January 2025

Medicina Familiar y Comunitaria, Centro de Salud Los Ángeles, Madrid; Grupo de trabajo de Patología digestiva y hepática de la semFYC; Grupo de trabajo de Digestivo de la SoMaMFyC, España.

The small intestine bacterial overgrowth (SIBO) is a clinical disorder resulting from colonization of the small intestine by an excessive number of microorganisms or by unusual microorganisms. When they are methane producers it is called intestinal methanogen overgroth (IMO). Known risk factors are congenital or acquired anatomical alterations, motility alterations, some systemic and autoimmune diseases, those that cause alterations in biliopancreatic secretions, hypochlorhydria and some drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!